u/elin_varga

Appeal deadlines run from the date on the determination letter. They are strict, they are short, and a missed deadline usually forfeits that level entirely.

Correction: that study measured regain after discontinuation, not loss of effect during treatment. Very different findings.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Fasting or not, and what time of day?

Small fix — external review is independent of the plan. The second-level internal appeal is not.

hold the dose that works, the ladder is not a leaderboard

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Are you comparing yourself with the trial mean or with the people who post the most?

25kg over 64 weeks, never went past 10mg, and early fullness stayed mild the whole way. Posting because the loud threads are all 15mg.

Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.

Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.

have the conversation with a clinician before, not after

A denial letter is required to state a reason and to reference the criterion applied.

elise_grimaldi is right that this is documentation rather than persuasion. It took me a year to accept that.

Withdrawal studies across this class consistently show substantial regain after discontinuation, with appetite typically returning before weight changes. That is a description of the pharmacology of a chronic condition.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

Correction to my own post above — I said 2.5mg and I have been on 15mg since the spring. Same argument, wrong number.

Have you held a step for longer than the four-week minimum at any point?

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

Careful — that is a question for whoever ordered the panel, and nobody in this thread can answer it responsibly.

My ApoB moved and I spent a fortnight convinced I knew why. The repeat six weeks later was back in range and I had changed nothing.

Prior authorisation criteria are republished each plan year.

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

Agreed. Province first — coverage is a provincial decision and national answers are wrong somewhere by construction.

Missed a deadline because I counted from when I opened the envelope. That mistake cost me an entire cycle.

Pen or vial? The step sizes available differ and it changes this answer.

the formulary is published, read it before you appeal

Spent six weeks arguing in general terms and got nowhere. Two paragraphs quoting their own criteria turned it around in eleven days.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

This. Asking what reference standard was used separates a real analytical claim from a plausible-looking one.

What is the waist doing? That is usually the number still moving during a scale stall.

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.